Pediatric use of topical ophthalmic drugs

Optometry

Volumn 75, Issue 7, 2004, Pages 419-429

  Coulter, Rachel Anastasia ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Children; Food and Drug Administration (FDA); Pediatric; Topical ophthalmic drugs; Treatment

Indexed keywords

AGENTS ACTING ON THE EYE; AMINOGLYCOSIDE; AZELASTINE; CHLORAMPHENICOL; CIPROFLOXACIN; CROMOGLYCATE DISODIUM; DEXAMETHASONE PLUS TOBRAMYCIN; EMEDASTINE; ERYTHROMYCIN; FLUOROMETHOLONE; GABAPENTIN; GATIFLOXACIN; KETOROLAC TROMETAMOL; KETOTIFEN FUMARATE; LEVOFLOXACIN; LODOXAMIDE TROMETAMOL; MOXIFLOXACIN; NEDOCROMIL SODIUM; OFLOXACIN; OLOPATADINE; PEMIROLAST; POLYTRIM; PROPOFOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFACETAMIDE; SULFANILAMIDE; TIMOLOL; TOBRAMYCIN; TRIFLURIDINE; UNINDEXED DRUG; DRUG; EYE DROPS;

ALLERGIC CONJUNCTIVITIS; CYANOSIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; EYE INFECTION; FOOD AND DRUG ADMINISTRATION; GRAY BABY SYNDROME; HUMAN; KERATOCONJUNCTIVITIS; REVIEW; CHILD; DRUG LEGISLATION; DRUG UTILIZATION; INFANT; PRESCHOOL CHILD; PRESCRIPTION; TOPICAL DRUG ADMINISTRATION; UNITED STATES;

ADMINISTRATION, TOPICAL; CHILD; CHILD, PRESCHOOL; DRUG APPROVAL; DRUG UTILIZATION; HUMANS; INFANT; LEGISLATION, DRUG; OPHTHALMIC SOLUTIONS; PHARMACEUTICAL PREPARATIONS; PRESCRIPTIONS, DRUG; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 4344714383     PISSN: 15291839     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1529-1839(04)70157-8     Document Type: Review

References (59)

1. Cote CJ. Adverse drug reactions and the package insert. Acta Paediatr 1999;88:925-7.
2. Nahata MC. (May 1997) Licensing of medicines for children in the USA. Paediatric and Perinatal Drug Therapy 1997. http://www.Priory.com/pharmol/ lomfcitu.html. Last accessed April 3, 2002.
3. Metry DW, Hebert AA. Topical therapies and medications in the pediatric patient. Pediatr Clin North Am 2000;47(4):867-76.
4. Shelton DL. (June 12, 2000). Pace picks up in pediatric studies. Amednews.com. http://www.ama-assn.org/sci-pubs/amnews/pick_00/hlsa0612.html. Last accessed April 3, 2003.
5. Modern regulatory environment shaped by pediatric pharmacology. Cited from Brown University Child and Adolescent Psychopharmacology Update 2002;4(5):1, 2-3. Medscape. http://www.medscape.com/viewartide/433244_print. Last accessed April 4, 2003).
6. Zenk KE. Challenges in providing pharmaceutical care to pediatric patients. Am J Hosp Pharm 1994;51:688-94.
7. Meadows M. Drug research and children. FDA Consum 2003;37(2):36.
8. Miller HI. The FDA drug approval process: focus on pediatric labeling [Letter to the editor]. Science 2002;296(5573):1609-10.
9. Wilson JT. An update on the therapeutic orphan. Pediatrics 1999;104:585-90.
10. Wilson JT, Kearns GL, Murphy D, et al. Paediatric labelling requirements: implications for pharmakinetic studies. Clin Pharmacokinet 1994;24:308-25.
11. Turner ST, Longworth A, Nunn AJ, et al. Unlicensed and off label drug use in paediatric wards: prospective study. Br Med J 1998;316:343-5.
12. Buck ML. (2000). The FDA Modernization Act of 1997: Impact on pediatric medicine. Cited from Pediatr Pharm 2000;6(12):2000. Medscape. http://www.medscape.com/viewarticle/410910. Last accessed September 27, 2003.
13. Bonetta L. Pediatric study of medicines becomes mandatory. Nat Med 2000;6:1069.
14. Pediatric clinical trials are on the rise as new law goes into effect. (August 9, 2000). Medscape Medical News. http://www.medscape.com/viewarticle/ 412078. Last accessed September 28, 2003.
15. Nordenberg T. Pediatric Drug Studies. FDA Consum 1999;33(4):23-8.
16. Cohen SN. The pediatric pharmacology research unit (PPRU) network and its role in meeting pediatric labeling needs. Pediatrics 1999;104:644-5.
17. Karst KR. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry. Am Univ Law Rev 2000;49:739-72.
18. FDA draft sets 50,000 pediatric prescription mentions/year threshold for research list. FDC Reports "The Pink Sheet" 1998;60(12):11-2.
19. FDA mandatory pediatric labeling rule would apply to first indication for NMEs, marketed products with wide use or important benefits in children. FDC Reports "The Pink Sheet" 1997;59(33):3-4.
20. HHS Identifies drugs for pediatric testing and announces FY 2003 and FY 2004 funding. News release (January 21, 2003) Health and Human Services, Washington, D.C. http://www.hhs.gov/news. Last accessed October 27, 2003.
21. Dove A. FDA in a quandary over Pediatric Rule. Nat Med 2002;8(6):541-2.
22. Safety-related labeling for pediatric drugs. Cited from Drug Benefit Trends 1999;11(1):11. Medscape. http://www.medscape.com/viewarticle/416823. Last accessed September 29, 2003.
23. Otto A. Industry heeds FDA call to add pediatric info to drug labels. Cited from Pharmacy Today 2001. 7(2). Medscape. http://www.medscape.com/ viewarticle/4066801, Last accessed September 29, 2003.
24. Plummer J. (May 2000). PDA's Pediatric Rule restricts access to medicine. Consumers' Research Magazine, www.consumeralert.org/pubs/research/CRMay00.html. Last accessed April 3, 2003.
25. Arshagouni P. (December 23, 2002). Federal court invalidates the FDA Pediatric Rule: AAPS v. FDA. httpp://www.law.uh.edu/healthlawperspectives/ Children/021223Federal.html. Last accessed April 3, 2003.
26. Association of American Physicians and Surgeons, Inc. v. U.S. Food and Drug Administration, 2002, U.S. Dist LEXIS 19689 http://www/law.uh.edu/ healthlawperspectives (D.D.C., October 17, 2002).
27. Barclay L. (November 6, 2002). Court overturns FDA Pediatric Rule: an expert interview with Philip Watson, M.D. Medscape Medical News, http://medscape.com/viewarticle/444180. Last accessed April 3, 2003.
28. (2003). Recent court decision invalidating PDA's Pediatric Rule. Biotechnology Industry Organization, http://www.bio.org/reg/pedrule.asp. Last accessed April 3, 2003.
29. Marshall E. Challenge to PDA's authority may end up giving it more. Science 2002;296:820-1.
30. Best Pharmaceuticals for Children Act. Public Law 107-109. p115 Stat. 1408.
31. Pediatric Pharmacy Administrative Group Committee on Pediatric Pharmacy Practice. Am J Hosp Pharm 1991;48:2475-7.
32. Koren G, Barzilay, Greenwald M. Tenfold errors in administration of drug doses: a neglected iatrogenic disease in pediatrics. Pediatrics 1986;177:848-9.
33. Jaanus SD. Pediatric pharmacology. In: Rosenbloom AA, Morgan MW, eds. Principles and practice of pediatric optometry. Philadelphia: JB Lippincott Co, 1990:293-312.
34. Mitchell A. (2001) Challenges in pediatric pharmacology: minimizing medication errors. Medscape Pharmacists 2 (10). http://www.medscape.com/ viewarticle/421220. Last accessed September 28, 2003.
35. The eye in childhood. Chicago: Yearbook Medical Publishers, Inc, 1967.
36. Liebman SD, Gellis SS, eds. Pediatric ophthalmology. St Louis: CV Mosby Co, 1966.
37. Palmer EA. How safe are ocular drugs in pediatrics? Ophthalmology 1984;91:1361-3.
38. Patton TF. Robinson JR. Pediatric considerations in ophthalmology. J Pediatr Ophthalmol 1976;13:171-8.
39. Havener WH. Ocular pharmacology, 4th ed. St Louis: CV Mosby, 1978:218-61.
40. Abelson MB, Paradis A, Grant KK. How to prescribe for the smallest sufferers. Rev Ophthalmol 1999;6(2):101-3.
41. Fraunfelder FT. Extraocular fluid dynamics: how best to apply topical ocular medication. Trans Am Ophthalmol Soc 1976;74:457-87.
42. Zimmerman TJ, Kooner KS, Kandarakis AS, et al. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol 1984;102:551-3.
43. Barlett JD, Wesson MD, Swiatochoa, et al. Efficacy of a pediatric cycloplegic administration as a spray. J AM OPTOM ASSOC 1993;64:617-21.
44. Ismail EE, Rouse MW, De Land PN. A comparison of drop instillation and spray application of 1% cyclopentolate. Optom Vis Sci 1994;71:235-41.
45. Benavides JO, Satchell ER, Frantz KA. Efficacy of a mydriatic spray in the pediatric population. Optom Vis Sci 1997;74:160-3.
46. Doe EA, Campagna JA. Pilocarpine spray: an alternative delivery method. J Ocul Pharmacol Ther 1998;14:1-4.
47. Akman A, Aydin P. Comparison of mydriatic efficacy of spray instillation and drop instillation of tropicamide 1%. Eye 1999;13:653-5.
48. Passo MS, Palmer EA, van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology 1984;91:1361-3.
49. Nagataki S, Mishima S. Pharmacokinetics of instilled drugs in the human eye. Int Ophthalmol Clin 1980;20(3):33-49.
50. Maurice DM. Factors influencing the penetration of topically applied drugs in the human eye. Int Ophthalmol Clin 1980;20:21-32.
51. Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol 1982;26:207-18.
52. Chrai SS, Patton TF, Mehta A, et al. Lacrimal and instilled fluid dynamics in rabbit eyes. J Pharm Sci 1973;62:1112-21.
53. Brown RH, Hotchkiss ML, Davis EB. Creating smaller eyedrops by reducing eyedropper tip dimensions. Am J Ophthalmol 1985;99:460-4.
54. Brown RH, Wood TS, Lynch MG, et al. Improving the therapeutic index of topical phenylephrine by reducing drop volume. Ophthalmology 1987;94(7):847-50.
55. Lynch MG, Reay HB, Goode SM, et al. Reduction of phenylephrine size in infants achieves equal dilation with decreased systemic absorption. Arch Ophthalmol 1987;105:1364-5.
56. Wheatcroft S, Sharma A, McAllister J. Reduction in mydriatic drop size in premature infants. Br J Ophthalmol 1993;77:364-5.
57. Walson PD, Getschman S, Koren G. Principles of drug prescribing in infants and children. A practical guide. Drugs 1993;46(2):281-8.
58. Connor JD. A look at the future of pediatric therapeutics: an investigator's perspective of the new pediatric rule. Pediatrics 1999;104(3):610-3.
59. Wilson RP. Lee DA, Netland PA, eds. The changing face of pediatric glaucomas. Rev Ophthalmol 2002;9(10):97-106.